1041672-46-1

Usage

Chemical structure

The compound has a 1,3,5-triazin-2-one core and a 4-amino-1-(3,5-di-O-acetyl-2-deoxy-a-D-erythro-pentofuranosyl) side chain.

Pharmaceutical use

It is commonly used in the pharmaceutical industry as an intermediate for the synthesis of nucleoside analogues.

Potential properties

The compound has potential antiviral and anticancer properties.

Research

Further research and studies are being conducted to explore the potential biological and pharmacological activities of 1,3,5-Triazin-2(1H)-one, 4-amino-1-(3,5-di-O-acetyl-2-deoxy-a-D-erythro-pentofuranosyl)-.

Building block

It is a valuable building block for the development of novel drugs and therapeutics.

Upstream product

• 52523-35-0 2-(trimethylsilylamino)-4-(trimethylsilyloxy)-s-triazine 
• 151767-35-0 3,5-di-O-acetyl-2-deoxy-α/β-D-ribofuranoside 
• 4594-52-9 1,3,5-tri-O-acetyl-2-deoxyribose 

Downstream Products

• 2353-33-5 5-aza-2'-deoxycytidine 

Relevant academic research and scientific papers

Synthesis and properties of cross-linkable DNA duplex using 4-amino-2-oxo-6-vinyl-1,3,5-triazine

We synthesized the DNA oligonucleotide containing a new cross-linkable 4-amino-2-oxo-6-vinyltriazine (AOVT) nucleobase analogue (Et-AOVT) and evaluated these properties. Our results of the cross-link assay and thermal denaturing assay of duplexes containing AOVT demonstrated that the additional aza of AOVT has an impact on the duplex stability and crosslink properties. Our data suggests that the additional 5-aza of AOVT is involved in the hydrogen bonding with the complementary guanine, and this hydrogen bonding system successfully flipped the reactive vinyl group out to the major groove of the duplex demonstrating a new paradigm of a “cross-linkable duplex”.

Method for synthesizing decitabine intermediate

The invention relates to a method for synthesizing a decitabine intermediate, in particular to a method for synthesizing the decitabine intermediate with a structure shown in a formula 2. According tothe method, the purity of the intermediate can be greatly improved, so that the purification operation of decitabine is reduced, a transition state intermediate compound is successfully separated forthe first time, and the total yield of decitabine is increased by three times.

Method for synthesizing decitabine key intermediate by solid acid catalysis

The invention belongs to the technical field of medicinal chemistry, and relates to a method for synthesizing a decitabine key intermediate (formula II) by solid acid catalysis. The method is characterized in that silicon dioxide loaded stannic chloride (SnCl4) is used as a catalyst for glycosylation reaction. The method has the advantages that the problem of complicated post treatment of a liquidacid catalyst is solved, and the content of beta-configuration intermediate can be effectively improved.

PREPARATION OF DECITABINE

The present application relates to processes for the preparation and purification of decitabine, and to processes for the preparation of a crystalline form of decitabine.